Back to search results
NCT07482644

Efficacy and Safety of an Essential Oil-Based Product System for Immune Support

Active, Not Recruiting
NAAges 18–45Interventional
dōTERRA International
~40 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:Essential Oil Blend (Botanical Combination Product)Placebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Immune Fitness Single-Item Scale (IFIS) Score
Measured over Baseline to Week 4
+4 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Nicole Stevens, PhD · PRINCIPAL_INVESTIGATOR · DoTERRA International LLC.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy male or female participants aged 18 to 45 years
Able to read, write, and understand English
Willing and able to attend study visits at the study site
Willing to comply with study procedures, including daily use of assigned study product for 30 days
Willing to refrain from use of essential oils (topical, aromatic, or internal) outside of the study during the study period
If previously using essential oils regularly (defined as more than 3 times per week for 2 or more weeks in the past month), must complete a washout period of at least 1 month prior to enrollment

Exclusion

Known asthma, chronic obstructive pulmonary disease (COPD), chronic lung disease, heart disease, or other medical condition that would make inhalation of essential oils unsafe, as determined by the investigator
Known allergy or hypersensitivity to essential oils or components of the placebo preparation
Current use of tobacco products, including smoking, vaping, or chewing tobacco
Use of recreational drugs
Pregnant or breastfeeding, or pregnancy within the past 3 months
Current regular use of essential oils (defined as more than 3 times per week for 2 or more weeks within the past month) without completion of a 1-month washout period
Initiation of new botanical supplements during the study period
Any medical, psychiatric, or social condition that, in the opinion of the investigator, would interfere with safe participation or study compliance

What this trial measures

  • Change in Immune Fitness Single-Item Scale (IFIS) ScoreBaseline to Week 4

    Within- and between-group change in perceived immune fitness as measured by the Immune Fitness Single-Item Scale (IFIS), a single-item scale ranging from 0 (very poor) to 10 (excellent), from baseline to Week 4. Weekly IFIS assessments will be used to estimate treatment effects over time. A higher score indicates a perception of greater/stronger immune fitness.

  • Change in Inflammatory Cytokine LevelsBaseline and Day 30

    Change from baseline to Day 30 in serum concentrations of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-10 (IL-10).

  • Change in Salivary Immunoglobulin A (IgA)Baseline and Day 30

    Change from baseline to Day 30 in salivary immunoglobulin A (IgA) concentration.

  • Change in Complete Blood Count (CBC) ParametersBaseline and Day 30

    Change from baseline to Day 30 in white blood cell count and differential as measured by complete blood count.

  • Change in Immune-Related Gene Expression MarkersBaseline and Day 30

    Change from baseline to Day 30 in epigenetic markers associated with immune regulation.